Sitemap Home argenx Group Shareholder Letter 2023 In Brief 2024 Outlook Company Profile Strategy and Objectives Our Products and Product Candidates VYVGART Efgartigimod Development Efgartigimod Indications Empasiprubart Development ARGX-119 Development ARGX-109, ARGX-220, ARGX-121 and ARGX-213 Development Immunology Innovation Program Collaborations and Licenses Distribution Agreements Manufacturing and Supply Intellectual Property Regulation Licensure and Regulation of Biologics in the U.S. Regulation and Procedures Governing Approval of Medicinal Products in the EU and the UK Regulation and Procedures Governing Approval of Medicinal Products in Japan Coverage, Pricing and Reimbursement Government Pricing and Reimbursement Programs for Marketed Drugs in the U.S. Healthcare Law and Regulation Healthcare Reform Environmental Issues which may Influence the Use of our Material Fixed Assets Documents on display Risk Factors Summary Financial Position and Additional Capital Commercialization Other Government Regulations Development and Clinical Testing Dependence on Third Parties Business and Industry Intellectual Property Organization and Operations American Depository Shares Being a Foreign Private Issuer or a Dutch Company Corporate Governance Dutch Corporate Governance Code Management Structure General Statement of the Board of Directors Board of Directors Non-Executive Directors Senior Management Conflict-of-Interest Transactions Code of Business Conduct and Ethics Report of the Non-Executive Directors Remuneration Report Say-on-pay and proposed Amendments to the Remuneration Policy 2023 Remuneration Named Executive Officer Remuneration Remuneration of Other Senior Management Members Non-Executive Remuneration Pay Ratios Other Disclosures Corporate Governance Share Ownership Insider Trading Cybersecurity Risk Appetite & Control Share Capital Legal Information on the Company Share Capital Share Classes and Principal Shareholders Limitations on the right to hold securities General Meeting, Voting Rights and Admission Anti-Takeover Provisions Exchange Controls Amendments of Articles of Association Transparency Directive Dutch Financial Reporting Supervision Act Dividends and Other Distributions Right to a surplus in the event of a liquidation Material Modifications to the Rights of Security Holders and Use of Proceeds Enforcement of civil liabilities Controls and Procedures Financial Calendar 2024 Financial Review Overview Basis of Presentation Capitalization and Indebtedness Critical Accounting Estimates and Judgments Results of Operation Liquidity and Capital Resources Research and Development, Patents and Licenses Trend Information Off-Balance Sheet Arrangements Contractual Obligations Information Regarding the Independent Auditor Material Contracts and Related Party Transactions Employees Insurance Legal and Arbitration Proceedings Taxation Financial Statements Consolidated Financial Statements Consolidated Statements of Financial Position Consolidated Statements of Profit or Loss Consolidated Statements of Comprehensive Income (Loss) Consolidated Statements of Cash Flows Consolidated Statements of Changes in Equity Notes to the Consolidated Financial Statements 1. General Information about the Company 2. Material Accounting Policy Information 3. Critical Accounting Estimates and Judgments 4. Property, Plant and Equipment 5. Intangible Assets 6. Other Non-Current Assets 7. Inventories 8. Prepaid Expenses (Current) 9. Trade and Other Receivables 10. Financial Assets – Current 11. Cash and Cash Equivalents 12. Share Capital and Share Premium 13. Share-Based Payments 14. Trade and Other Payables 15. Product Net Sales 16. Collaboration Revenue 17. Other Operating Income 18. Segment Reporting 19. Research and Development Expenses 20. Selling, General and Administrative Expenses 21. Personnel Expenses 22. Leases 23. Financial Result and Exchange Gains/(Losses) 24. Income taxes 25. Loss per Share 26. Financial Risk Management 27. Related Party Transactions 28. Contingencies 29. Commitments 30. Audit Fees 31. Overview of Consolidation Scope 32. Events After the Balance Sheet Date Company Financial Statements Signatures of Executive and Non-Executive Directors Company Financial Statements for argenx SE Notes to the Company Financial Statements Other Information Independent Auditor’s Report Non-Financial Information Regulations and Compliance NFRD EU Taxonomy Patient Stories Glossary Cross Reference table for annual reporting requirement Management Confirmations Definitions
